19:01 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Galmed raises $75M follow-on

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) raised $75 million through the sale of 5 million shares at $15 in a follow-on underwritten by Stifel, SunTrust Robinson Humphrey, Cantor Fitzgerald, Raymond James, Roth Capital Partners, Maxim Group and...
18:45 , Jun 20, 2018 |  BC Extra  |  Financial News

Galmed raises $75M follow-on

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) raised $75 million through the sale of 5 million shares at $15 in a follow-on underwritten by Stifel, SunTrust Robinson Humphrey, Cantor Fitzgerald, Raymond James, Roth Capital Partners, Maxim Group and...
20:41 , Jun 14, 2018 |  BC Week In Review  |  Clinical News

After NASH readout, Galmed looks to Phase III

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) said data from the Phase IIb ARREST trial showed that once-daily oral Aramchol arachidyl amino cholanoic acid led to disease improvements in patients with non-alcoholic steatohepatitis (NASH). Galmed said the data...
18:33 , Jun 12, 2018 |  BC Extra  |  Clinical News

After NASH readout, Galmed looks to Phase III

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) gained $10.54 (150%) to $17.59 on Tuesday after it said data from the Phase IIb ARREST trial showed that once-daily oral Aramchol arachidyl amino cholanoic acid led to disease improvements in...
19:40 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Galmed's Aramchol misses in Phase IIa for HIV-associated NAFLD

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) said Aramchol arachidyl amino cholanoic acid missed the primary endpoint in the Phase IIa ARRIVE trial to treat HIV-associated lipodystrophy and non-alcoholic fatty liver disease (NAFLD). The company said it has...
19:51 , Feb 14, 2018 |  BC Extra  |  Clinical News

Galmed falls on Phase IIa HIV-associated NAFLD miss

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was down $4.01 (42%) to $5.45 on Wednesday after reporting that Aramchol arachidyl amino cholanoic acid missed the primary endpoint in the Phase IIa ARRIVE trial to treat HIV-associated lipodystrophy and...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

Aramchol arachidyl amino cholanoic acid: Phase IIa started

Galmed began the double-blind, placebo-controlled, U.S. Phase IIa ARRIVE trial to evaluate 600 mg oral Aramchol once daily for 12 weeks in up to 50 patients with HIV-associated lipodystrophy and NAFLD. Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD),...
07:00 , Sep 3, 2015 |  BC Innovations  |  Targets & Mechanisms

Low-fat brain

While most of the focus in Alzheimer's disease is on slowing or stopping the degeneration of neurons, a team at the University of Montreal has found that one cause of the disease could lie in...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Galmed Pharmaceuticals, OWL deal

The companies partnered to develop a non-invasive, blood-based companion diagnostic for Aramchol arachidyl amino cholanoic acid to treat non-alcoholic steatohepatitis (NASH). Galmed is conducting the Phase IIb ARREST trial of the synthetic conjugate of cholic...
00:42 , Jul 9, 2015 |  BC Extra  |  Company News

Galmed, OWL aim to develop NASH diagnostic

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) partnered with One Way Liver Genomics S.L. (Derio, Spain) to develop a non-invasive, blood-based companion diagnostic for Aramchol arachidyl amino cholanoic acid to treat non-alcoholic steatohepatitis (NASH). Galmed is conducting the...